Abstract ISI
ARTHRITIS AND RHEUMATISM  (2005)

Tumor necrosis factor-alpha-308 G/G promoter polymorphism correlates with a better response to adalimumab in patients with rheumatoid arthritis.

Cuchacovich M.; Soto L.; Edwardes, M; Gutierrez M.; Llanos C.; Pacheco D.; Sabugo F.; Alamo M.; Fuentealba C.; Villanueva L.; Gatica H.; Schiattino, I; Salazar L.; Catalan D.; Valenzuela O.; et. al.